Resveratrol and clinical trials: The crossroad from in vitro studies to human evidence

Current Pharmaceutical Design

Volumn 19, Issue 34, 2013, Pages 6064-6093

  Tomé Carneiro, Joao ^a   Larrosa, Mar ^a   González Sarrías, Antonio ^a   Tomás Barberán, Francisco A ^a   García Conesa, María Teresa ^a   Espín, Juan Carlos ^a  

^a RESEARCH GROUP ON QUALITY   (Spain)

Author keywords

Cancer; Cardiovascular; Clinical trials; Nutraceutical; Polyphenol; Resveratrol

Indexed keywords

BORTEZOMIB; CALCIUM DERIVATIVE; CALCIUM FRUCTOBORATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ORAL CONTRACEPTIVE AGENT; PHYTOALEXIN; PLACEBO; POLYPHENOL; RESVERATROL; STILBENE DERIVATIVE; UNCLASSIFIED DRUG;

ADD ON THERAPY; AGING; ANTICOAGULATION; ANTIDIABETIC ACTIVITY; ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ATHEROSCLEROSIS; BREAST CANCER; CANCER PREVENTION; CARDIOVASCULAR DISEASE; COLON CANCER; COLORECTAL CANCER; DEGENERATIVE DISEASE; DIABETES MELLITUS; DIETARY INTAKE; DISEASE MODEL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; DRUG SAFETY; FOOD INTAKE; HEALTH STATUS; HEART FAILURE; HEART PROTECTION; HUMAN; HYPERTENSION; IN VITRO STUDY; INTERVENTION STUDY; LIVER METASTASIS; METABOLIC SYNDROME X; MULTIPLE MYELOMA; NAUSEA AND VOMITING; NONHUMAN; OBESITY; POLYGONUM CUSPIDATUM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE; SKIN CANCER; STABLE ANGINA PECTORIS; THROMBOCYTE AGGREGATION INHIBITION; VERATRUM;

ANIMALS; ANTICARCINOGENIC AGENTS; CARDIOVASCULAR AGENTS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; EVIDENCE-BASED MEDICINE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STILBENES; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 84886461893     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990407     Document Type: Review

References (328)

1. Tomás-Barberán FA, Espín JC. Phenolic compounds and related enzymes as determinants of quality in fruits and vegetables. J Sci Food Agric 2001; 81: 853-76.
2. Waterhouse AL. Wine phenolics. Ann N Y Acad Sci 2002; 957: 21-36.
3. Scalbert A, Williamson G. Dietary intake and bioavailability of polyphenols. J Nutr 2000; 130: 2073S-85S.
4. Williamson G, Manach C. Bioavailability and bioefficacy of polyphenols in humans. II. Review of 93 intervention studies. Am J Clin Nutr 2005; 81: 243S-255S.
5. Hooper L, Kay C, Abdelhamid A, Kroon PA, et al. Effects of chocolate, cocoa, and flavan-3-ols on cardiovascular health: a systematic review and meta-analysis of randomized trials. Am J Clin Nutr 2012; 95: 740-51.
6. Andrade JP, Assunção M. Protective effects of chronic green tea consumption on age-related neurodegeneration. Curr Pharm Des 2012; 18: 4-14.
7. Visioli F, Bernardini E. Extra virgin olive oil's polyphenols: biological activities. Curr Pharm Des 2011; 17: 786-804.
8. Urpí-Sarda M, Casas R, Chiva-Blanch G, Romero-Mamani ES, et al. Virgin olive oil and nuts as key foods of the Mediterranean diet effects on inflammatory biomakers related to atherosclerosis. Pharmacol Res 2012; 65: 577-83.
9. Li H, Förstermann U. Red wine and cardiovascular health. Circ Res 2012; 111: 959-61.
10. Stervbo U, Vang O, Bonnesen C. A review of the content of the putative chemopreventive phytoalexin resveratrol in red wine. Food Chem 2007; 101: 449-57.
11. Takaoka MJ. Of the phenolic substances of white hellebore (Veratrum grandiflorum Loes. fil.). J Faculty Sci Hokkaido Imperial University 1940; 3: 1-16.
12. Nonomura S, Kanagawa H, and Makimoto A. [Chemical Constituents of Polygonaceous Plants. I. Studies on the Components of Ko-J O-Kon. (Polygonum Cuspidatum Sieb. et Zucc.)]. Yakugaku Zasshi 1963; 83: 988-90.
13. Siemann EH, Creasy LL. Concentration of the phytoalexin resveratrol in wine. Am J Enol Vitic 1992; 43: 49-52.
14. Bertelli AA, Giovannini L, Giannessi D, Migliori, et al. Antiplatelet activity of synthetic and natural resveratrol in red wine. Int J Tissue React 1995; 17: 1-3.
15. Jang M, Cai L, Udeani GO, Slowing KV, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997; 275: 218-20.
16. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006; 5: 493-506.
17. Vang O, Ahmad N, Baile CA, Baur JA, et al. What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS One 2011; 6: e19881.
18. Li F, Gong Q, Dong H, Shi J. Resveratrol, a neuroprotective supplement for Alzheimer's disease. Curr Pharm Des 2012; 18: 27-33.
19. Renaud S, de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 1992; 339: 1523-6.
20. Micallef M, Lexis L, Lewandowski P. Red wine consumption increases antioxidant status and decreases oxidative stress in the circulation of both young and old humans. Nutr J 2007; 6: 27.
21. Guarda E, Godoy I, Foncea R, Pérez DD, et al. Red wine reduces oxidative stress in patients with acute coronary syndrome. Int J Cardiol 2005; 104: 35-8.
22. Bertelli A, Bertelli AA, Gozzini A, Giovannini L. Plasma and tissue resveratrol concentrations and pharmacological activity. Drugs Exp Clin Res 1998; 24: 133-8.
23. Langcake P, Pryce RJ. The production of resveratrol by Vitis vinifera and other members of the Vitaceae as a response to infection or injury. Physiol. Plant Pathol 1976; 9: 77-86.
24. Cantos E, Espín JC, Fernández MJ, Oliva J, et al. Postharvest UVC-irradiated grapes as a potential source for producing stilbeneenriched red wines. J Agric Food Chem 2003; 51: 1208-14.
25. Cantos E, Espín JC, Tomás-Barberán FA. Postharvest stilbeneenrichment of red and white table grape varieties using UV-C irradiation pulses. J Agric Food Chem 2002; 50: 6322-9.
26. Cantos E, Espín JC, Tomás-Barberán FA. Postharvest induction modeling method using UV irradiation pulses for obtaining resveratrol-enriched table grapes: a new "functional" fruit? J Agric Food Chem 2001; 49: 5052-8.
27. Zamora-Ros R, Andres-Lacueva C, Lamuela-Raventós RM, Berenguer T, et al. Concentrations of resveratrol and derivatives in foods and estimation of dietary intake in a Spanish population: European Prospective Investigation into Cancer and Nutrition (EPIC)-Spain cohort. Br J Nutr 2008; 100: 188-96.
28. Goldberg DM, Yan J, Soleas GJ. Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin Biochem 2003; 36: 79-87.
29. Walle T, Hsieh F, DeLegge MH, Oatis, JE Jr, et al. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 2004; 32: 1377-82.
30. Brown VA, Patel KR, Viskaduraki M, Crowell JA, et al. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res 2010; 70: 9003-11.
31. Athar M, Back JH, Kopelovich L, Bickers DR, et al. Multiple molecular targets of resveratrol: Anti-carcinogenic mechanisms. Arch Biochem Biophys 2009; 486: 95-102.
32. Shakibaei M, Harikumar KB, Aggarwal BB. Resveratrol addiction: To die or not to die. Mol Nutr Food Res 2009; 53: 115-28.
33. Yu W, Fu YC, Wang W. Cellular and Molecular Effects of resveratrol in Health and Disease. J Cell Biochem 2012; 113: 752-9.
34. Aluyen JK, Ton QN, Tran T, Yang AE, et al. Resveratrol: potential as anticancer agent. J Diet Suppl 2012; 9: 45-56.
35. Le Corre L, Chalabi N, Delort L, Bignon YJ, et al. Resveratrol and breast cancer chemoprevention: molecular mechanisms. Mol Nutr Food Res 2005; 49: 462-71.
36. Bishayee A, Politis T, Darvesh AS. Resveratrol in the chemoprevention and treatment of hepatocellular carcinoma. Cancer Treat Rev 2010; 36: 43-53.
37. Juan ME, Alfaras I, Planas JM. Colorectal cancer chemoprevention by trans-resveratrol. Pharmacol Res 2012; 65: 584-91.
38. Wolter F, Akoglu B, Clausnitzer A, Stein J. Downregulation of the cyclin D1/Cdk4 complex occurs during resveratrol-induced cell cycle arrest in colon cancer cell lines. J Nutr 2001; 131: 2197-203.
39. Benitez DA, Pozo-Guisado E, Alvarez-Barrientos A, Fernandez-Salguero PM, et al. Mechanisms involved in resveratrol-induced apoptosis and cell cycle arrest in prostate cancer-derived cell lines. J Androl 2007; 28: 282-93.
40. Gatouillat G, Balasse E, Joseph-Pietras D, Morjani H, et al. Resveratrol induces cell-cycle disruption and apoptosis in chemoresistant B16 melanoma. J Cell Biochem 2010; 110: 893-902.
41. Bai Y, Mao QQ, Qin J, Zheng XY, et al. Resveratrol induces apoptosis and cell cycle arrest of human T24 bladder cancer cells in vitro and inhibits tumor growth in vivo. Cancer Sci 2010; 101: 488-93.
42. Vanamala J, Radhakrishnan S, Reddivari L, Bhat VB, et al. Resveratrol suppresses human colon cancer cell proliferation and induces apoptosis via targeting the pentose phosphate and the talin-FAK signaling pathways-A proteomic approach. Proteome Sci 2011; 9: 49.
43. Ferry-Dumazet H, Garnier O, Mamani-Matsuda M, Dupouy M, et al. Trans-resveratrol inhibits the growth and induces the apoptosis of both normal and leukemic hematopoietic cells. Carcinogenesis 2002; 23: 1327-33.
44. Filippi-Chiela EC, Villodre ES, Zamin LL, Lenz G. Autophagy interplay with apoptosis and cell cycle regulation in the growth inhibiting effect of resveratrol in glioma cells. PLoS One 2011; 6: e20849.
45. Alkhalaf M, Jaffal S. Potent antiproliferative effects of resveratrol on human osteosarcoma SJSA1 cells: Novel cellular mechanisms involving the ERKs/p53 cascade. Free Radic Biol Med 2006; 41: 318-25.
46. Rashid A, Liu C, Sanli T, Tsiani E, et al. Resveratrol enhances prostate cancer cell response to ionizing radiation. Modulation of the AMPK, Akt and mTOR pathways. Radiat Oncol 2011; 6: 144.
47. Liao PC, Ng LT, Lin LT, Richardson CD, et al. Resveratrol arrests cell cycle and induces apoptosis in human hepatocellular carcinoma Huh-7 cells. J Med Food 2010; 13: 1415-23.
48. Hsieh TC, Wong C, John Bennett D, Wu JM. Regulation of p53 and cell proliferation by resveratrol and its derivatives in breast cancer cells: an in silico and biochemical approach targeting integrin v 3. Int J Cancer 2011; 129: 2732-43.
49. Sareen D, van Ginkel PR, Takach JC, Mohiuddin A, et al. Mitochondria as the primary target of resveratrol-induced apoptosis in human retinoblastoma cells. Invest Ophthalmol Vis Sci 2006; 47: 3708-16.
50. Aziz MH, Nihal M, Fu VX, Jarrard DF, et al. Resveratrol-caused apoptosis of human prostate carcinoma LNCaP cells is mediated via modulation of phosphatidylinositol 3'-kinase/Akt pathway and Bcl-2 family proteins. Mol Cancer Ther 2006; 5: 1335-41.
51. Li G, He S, Chang L, Lu H, et al. GADD45 and annexin A1 are involved in the apoptosis of HL-60 induced by resveratrol. Phytomedicine 2011; 18: 704-9.
52. Lin X, Wu G, Huo WQ, Zhang Y, et al. Resveratrol induces apoptosis associated with mitochondrial dysfunction in bladder carcinoma cells. Int J Urol 2012; 19: 757-64.
53. Bhardwaj A, Sethi G, Vadhan-Raj S, Bueso-Ramos C, et al. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood 2007; 109: 2293-302.
54. Faber AC, Dufort FJ, Blair D, Wagner D, et al. Inhibition of phosphatidylinositol 3-kinase-mediated glucose metabolism coincides with resveratrol-induced cell cycle arrest in human diffuse large Bcell lymphomas. Biochem Pharmacol 2006; 72: 1246-56.
55. Puissant A, Robert G, Fenouille N, Luciano F, et al. Resveratrol promotes autophagic cell death in chronic myelogenous leukemia cells via JNK-mediated p62/SQSTM1 expression and AMPK activation. Cancer Res 2010; 70: 1042-52.
56. Wang Y, Romigh T, He X, Orloff MS, et al. Resveratrol regulates the PTEN/AKT pathway through androgen receptor-dependent and-independent mechanisms in prostate cancer cell lines. Hum Mol Genet 2010; 19: 4319-29.
57. Banerjee Mustafi S, Chakraborty PK, Raha S. Modulation of Akt and ERK1/2 pathways by resveratrol in chronic myelogenous leukemia (CML) cells results in the downregulation of Hsp70. PLoS One 2010; 5: e8719.
58. Parekh P, Motiwale L, Naik N, Rao KV. Downregulation of cyclin D1 is associated with decreased levels of p38 MAP kinases, Akt/PKB and Pak1 during chemopreventive effects of resveratrol in liver cancer cells. Exp Toxicol Pathol 2011; 63: 167-73.
59. Chen Q, Ganapathy S, Singh KP, Shankar S, et al. Resveratrol induces growth arrest and apoptosis through activation of FOXO transcription factors in prostate cancer cells. PLoS One 2010; 5: e15288.
60. He X, Wang Y, Zhu J, Orloff M, et al. Resveratrol enhances the anti-tumor activity of the mTOR inhibitor rapamycin in multiple breast cancer cell lines mainly by suppressing rapamycin-induced AKT signaling. Cancer Lett 2011; 301: 168-76.
61. Chen J, Zhou Y, Mueller-Steiner S, Chen LF, et al. SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling. J Biol Chem 2005; 280: 40364-74.
62. Pozo-Guisado E, Merino JM, Mulero-Navarro S, Lorenzo-Benayas MJ, et al. Resveratrol-induced apoptosis in MCF-7 human breast cancer cells involves a caspase-independent mechanism with downregulation of Bcl-2 and NF-kappaB. Int J Cancer 2005; 115: 74-84.
63. Yu H, Pan C, Zhao S, Wang Z, et al. Resveratrol inhibits tumor necrosis factor-alpha-mediated matrix metalloproteinase-9 expression and invasion of human hepatocellular carcinoma cells. Biomed Pharmacother 2008; 62: 366-72.
64. Lee MF, Pan MH, Chiou YS, Cheng AC, et al. Resveratrol modulates MED28 (Magicin/EG-1) expression and inhibits epidermal growth factor (EGF)-induced migration in MDA-MB-231 human breast cancer cells. J Agric Food Chem 2011; 59: 11853-61.
65. Hope C, Planutis K, Planutiene M, Moyer MP, et al. Low concentrations of resveratrol inhibit Wnt signal throughput in colonderived cells: implications for colon cancer prevention. Mol Nutr Food Res 2008; 52: S52-61.
66. Vanamala J, Reddivari L, Radhakrishnan S, Tarver C. Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt and activation of p53 signaling pathways. BMC Cancer 2010; 10: 238.
67. Ulrich S, Loitsch SM, Rau O, von Knethen A, et al. Peroxisome proliferator-activated receptor gamma as a molecular target of resveratrol-induced modulation of polyamine metabolism. Cancer Res 2006; 66: 7348-54.
68. Colin D, Limagne E, Jeanningros S, Jacquel A, et al. Endocytosis of resveratrol via lipid rafts and activation of downstream signaling pathways in cancer cells. Cancer Prev Res 2011; 4: 1095-106.
69. Castino R, Pucer A, Veneroni R, Morani F, et al. Resveratrol reduces the invasive growth and promotes the acquisition of a longlasting differentiated phenotype in human glioblastoma cells. J Agric Food Chem 2011; 59: 4264-72.
70. Weng CJ, Wu CF, Huang HW, Wu CH, et al. Evaluation of antiinvasion effect of resveratrol and related methoxy analogues on human hepatocarcinoma cells. J Agric Food Chem 2010; 58: 2886-94.
71. Annabi B, Lord-Dufour S, Vézina A, Béliveau R. Resveratrol Targeting of Carcinogen-Induced Brain Endothelial Cell Inflammation Biomarkers MMP-9 and COX-2 is Sirt1-Independent. Drug Target Insights 2012; 6: 1-11.
72. Vergara D, Valente CM, Tinelli A, Siciliano C, et al. Resveratrol inhibits the epidermal growth factor-induced epithelial mesenchymal transition in MCF-7 cells. Cancer Lett 2011; 310: 1-8.
73. Bournival J, Quessy P, Martinoli MG. Protective effects of resveratrol and quercetin against MPP+-induced oxidative stress act by modulating markers of apoptotic death in dopaminergic neurons. Cell Mol Neurobiol 2009; 29: 1169-80.
74. Han YS, Zheng WH, Bastianetto S, Chabot JG, et al. Neuroprotective effects of resveratrol against beta-amyloid-induced neurotoxicity in rat hippocampal neurons: involvement of protein kinase C. Br J Pharmacol 2004; 141: 997-1005.
75. Marambaud P, Zhao H, Davies P. Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. J Biol Chem 2005; 280: 37377-82.
76. Vingtdeux V, Giliberto L, Zhao H, Chandakkar P, et al. AMPactivated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism. J Biol Chem 2010; 285: 9100-13.
77. Leonard SS, Xia C, Jiang BH, Stinefelt B, et al. Resveratrol scavenges reactive oxygen species and effects radical-induced cellular responses. Biochem Biophys Res Commun 2003; 309: 1017-26.
78. Chow SE, Hshu YC, Wang JS, Chen JK. Resveratrol attenuates oxLDL-stimulated NADPH oxidase activity and protects endothelial cells from oxidative functional damages, J Appl Physiol 2007; 102: 1520-7.
79. Zhang F, Shi JS, Zhou H, Wilson B, et al. Resveratrol protects dopamine neurons against lipopolysaccharide-induced neurotoxicity through its anti-inflammatory actions. Mol Pharmacol 2010; 78: 466-77.
80. Spanier G, Xu H, Xia N, Tobias S, et al. Resveratrol reduces endothelial oxidative stress by modulating the gene expression of superoxide dismutase 1 (SOD1), glutathione peroxidase 1 (GPx1) and NADPH oxidase subunit (Nox4). J Physiol Pharmacol 2009; 60: 111-6.
81. Xia N, Daiber A, Habermeier A, Closs EI, et al. Resveratrol reverses endothelial nitric-oxide synthase uncoupling in apolipoprotein E knockout mice. J Pharmacol Exp Ther 2010; 335: 149-54.
82. Ungvari Z, Labinskyy N, Mukhopadhyay P, Pinto JT, et al. Resveratrol attenuates mitochondrial oxidative stress in coronary arterial endothelial cells. Am J Physiol Heart Circ Physiol 2009; 297: H1876-81.
83. Tanno M, Kuno A, Yano T, Miura T, et al. Induction of manganese superoxide dismutase by nuclear translocation and activation of SIRT1 promotes cell survival in chronic heart failure. J Biol Chem 2010; 285: 8375-82.
84. Kaga S, Zhan L, Matsumoto M, Maulik N. Resveratrol enhances neovascularization in the infarcted rat myocardium through the induction of thioredoxin-1, heme oxygenase-1 and vascular endothelial growth factor. J Mol Cell Cardiol 2005; 39: 813-22.
85. Zhuang H, Kim YS, Koehler RC, Doré S. Potential mechanism by which resveratrol, a red wine constituent, protects neurons. Ann N Y Acad Sci 2003; 993: 276-6.
86. Thirunavukkarasu M, Penumathsa SV, Koneru S, Juhasz B, et al. Resveratrol alleviates cardiac dysfunction in streptozotocininduced diabetes: role of nitric oxide, thioredoxin and heme oxygenase. Free Radic Biol Med 2007; 43: 720-9.
87. Juan SH, Cheng TH, Lin HC, Chu YL, et al. Mechanism of concentration-dependent induction of heme oygenase-1 by resveratrol in human aortic smooth muscle cells. Biochem Pharmacol 2005; 69: 41-8.
88. Yang J, Wang N, Li J, Zhang J, et al. Effects of resveratrol on NO secretion stimulated by insulin and its dependence on SIRT1 in high glucose cultured endothelial cells. Endocrine 2010; 37: 365-72.
89. Takahashi S, Nakashima Y. Repeated and long-term treatment with physiological concentrations of resveratrol promotes NO production in vascular endothelial cells. Br J Nutr 2012; 107: 774-80.
90. Klinge CM, Wickramasinghe NS, Ivanova MM, Dougherty SM. Resveratrol stimulates nitric oxide production by increasing estrogen receptor alpha-Src-caveolin-1 interaction and phosphorylation in human umbilical vein endothelial cells. FASEB J 2008; 22: 2185-97.
91. Elíes J, Cuíñas A, García-Morales V, Orallo F, et al. Transresveratrol simultaneously increases cytoplasmic Ca(2+) levels and nitric oxide release in human endothelial cells. Mol Nutr Food Res 2011; 55: 1237-48.
92. Csiszar A, Labinskyy N, Pinto JT, Ballabh P, et al. Resveratrol induces mitochondrial biogenesis in endothelial cells. Am J Physiol Heart Circ Physiol 2009; 297: H13-20.
93. Wallerath T, Deckert G, Ternes T, Anderson H, et al. Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. Circulation 2002; 106: 1652-8.
94. Arunachalam G, Yao H, Sundar IK, Caito S, et al. SIRT1 regulates oxidant-and cigarette smoke-induced eNOS acetylation in endothelial cells: role of resveratrol. Biochem Biophys Res Commun 2010; 393: 66-72.
95. Klinge CM, Blankenship KA, Risinger KE, Bhatnagar S, et al. Resveratrol and estradiol rapidly activate MAPK signaling through estrogen receptors alpha and beta in endothelial cells. J Biol Chem 2005; 280: 7460-8.
96. Xu Q, Hao X, Yang Q, Si L. Resveratrol prevents hyperglycemiainduced endothelial dysfunction via activation of adenosine monophosphate-activated protein kinase. Biochem Biophys Res Commun 2009; 388: 389-94.
97. Park SJ, Ahmad F, Philp A, Baar K, et al. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 2012; 148: 421-33.
98. Ungvari Z, Bagi Z, Feher A, Recchia FA, et al. Resveratrol confers endothelial protection via activation of the antioxidant transcription factor Nrf2. Am J Physiol Heart Circ Physiol 2010; 299: H18-24.
99. Moon SO, Kim W, Sung MJ, Lee S et al. Resveratrol suppresses tumor necrosis factor-alpha-induced fractalkine expression in endothelial cells. Mol. Pharmacol 2006; 70: 112-9.
100. Csiszar A, Smith K, Labinskyy N, Orosz Z, et al. Resveratrol attenuates TNF-alpha-induced activation of coronary arterial endothelial cells: role of NF-kappaB inhibition. Am J Physiol Heart Circ Physiol 2006; 291: H1694-9.
101. Cicha I, Regler M, Urschel K, Goppelt-Struebe M, et al. Resveratrol inhibits monocytic cell chemotaxis to MCP-1 and prevents spontaneous endothelial cell migration through Rho kinasedependent mechanism. J Atheroscler Thromb 2011; 18: 1031-42.
102. Csiszar A, Labinskyy N, Podlutsky A, Kaminski PM, et al. Vasoprotective effects of resveratrol and SIRT1: attenuation of cigarette smoke-induced oxidative stress and proinflammatory phenotypic alterations. Am J Physiol Heart Circ Physiol 2008; 294: H2721-35.
103. Sayin O, Arslan N, Altun ZS, Akdogan G. In vitro effect of resveratrol against oxidative injury of human coronary artery endothelial cells. Turk J Med Sci 2011; 41: 211-8.
104. Holmes-McNary M, Baldwin AS Jr. Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the IkappaB kinase. Cancer Res 2000; 60: 3477-83.
105. Wang Z, Chen Y, Labinskyy N, Hsieh TC, et al. Regulation of proliferation and gene expression in cultured human aortic smooth muscle cells by resveratrol and standardized grape extracts. Biochem Biophys Res Commun 2006; 346: 367-76.
106. Ferrero ME, Bertelli AE, Fulgenzi A, Pellegatta F, et al. Activity in vitro of resveratrol on granulocyte and monocyte adhesion to endothelium. Am J Clin Nutr 1998; 68: 1208-14.
107. Kim SW, Kim CE, Kim MH. Flavonoids inhibit high glucoseinduced up-regulation of ICAM-1 via the p38 MAPK pathway in human vein endothelial cells. Biochem Biophys Res Commun 2011; 415: 602-7.
108. Subbaramaiah K, Chung WJ, Michaluart P, Telang N, et al. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J Biol Chem 1998; 273: 21875-82.
109. Dave M, Attur M, Palmer G, Al-Mussawir HE, et al. The antioxidant resveratrol protects against chondrocyte apoptosis via effects on mitochondrial polarization and ATP production. Arthritis Rheum 2008; 58: 2786-97.
110. Picard F, Kurtev M, Chung N, Topark-Ngarm A, et al. Sirt1 promotes fat mobilization in white adipocytes by repressing PPARgamma. Nature 2004; 429: 771-6.
111. Rayalam, S, Yang JY, Ambati S, Della-Fera MA, et al. Resveratrol induces apoptosis and inhibits adipogenesis in 3T3-L1 adipocytes. Phytotherapy Res 2008; 22: 1367-71.
112. Szkudelska K, Nogowski L, Szkudelski T. Resveratrol, a naturally occurring diphenolic compound, affects lipogenesis, lipolysis and the antilipolytic action of insulin in isolated rat adipocytes. J Steroid Biochem Mol Biol 2009; 113: 17-24.
113. Fischer-Posovszky P, Kukulus V, Tews D, Unterkircher T, et al. Resveratrol regulates human adipocyte number and function in a Sirt1-dependent manner. Am J Clin Nutr 2010; 92: 5-15.
114. Mader I, Wabitsch M, Debatin KM, Fischer-Posovszky P, et al. Identification of a novel proapoptotic function of resveratrol in fat cells: SIRT1-independent sensitization to TRAIL-induced apoptosis. Faseb J 2010; 24: 1997-2009.
115. Lasa A, Churruca I, Eseberri I, Andrés-Lacueva C, et al. Delipidating effect of resveratrol metabolites in 3T3-L1 adipocytes. Mol Nutr Food Res 2012; 56: 1559-68.
116. Shen MY, Hsiao G, Liu CL, Fong TH, et al. Inhibitory mechanisms of resveratrol in platelet activation: pivotal roles of p38 MAPK and NO/cyclic GMP. Br J Haematol 2007; 139: 475-85.
117. Yang YM, Chen JZ, Wang XX, Wang SJ, et al. Resveratrol attenuates thromboxane A2 receptor agonist induced platelet activation by reducing phospholipase C activity. Eur J Pharmacol 2008; 583: 148-55.
118. Lin KH, Hsiao G, Shih CM, Chou DS, et al. Mechanisms of resveratrol induced platelet apoptosis. Cardiovasc Res 2009; 83: 575-85.
119. Stefani M, Markus MA, Lin RC, Pinese M, et al. The effect of resveratrol on a cell model of human aging. Ann N Y Acad Sci 2007; 1114: 407-18.
120. Tang Y, Xu J, Qu W, Peng X, et al. Resveratrol reduces vascular cell senescence through attenuation of oxidative stress by SIRT1/NADPH oxidase-dependent mechanisms. J Nutr Biochem 2012; 23: 1410-6.
121. Wu A, Ying Z, Gomez-Pinilla F. Oxidative stress modulates Sir2alpha in rat hippocampus and cerebral cortex. Eur J Neurosci 2006; 23: 2573-80.
122. Bove K, Lincoln DW, Tsan MF. Effect of resveratrol on growth of 4T1 breast cancer cells in vitro and in vivo. Biochem Biophys Res Commun 2002; 291: 1001-5.
123. Ziegler CC, Rainwater L, Whelan J, McEntee MF. Dietary resveratrol does not affect intestinal tumorigenesis in Apc (Min/+) mice. J Nutr 2004; 134: 5-10.
124. Berge G, Ovrebo S, Eilertsen E, Haugen A, et al. Analysis of resveratrol as a lung cancer chemopreventive agent in A/J mice exposed to benzo [alpha] pyrene. Br J Cancer 2004; 91: 1380-3.
125. Niles RM, Cook CP, Meadows GG, Fu YM, et al. Resveratrol is rapidly metabolized in athymic (Nu/Nu) mice and does not inhibit human melanoma xenograft tumor growth. J Nutr 2006; 136: 2542-6.
126. Zunino SJ, Storms DH, Newman JW, Pedersen TL, et al. Resveratrol given intraperitoneally does not inhibit the growth of high-risk t (4; 11) acute lymphoblastic leukemia cells in a NOD/SCID mouse model. Int J Oncol 2012; 40: 1277-84.
127. Stakleff KS, Sloan T, Blanco D, Marcanthony S, et al. Resveratrol exerts differential effects in vitro and in vivo against ovarian cancer cells. Asian Pac J Cancer Prev 2012; 13: 1333-40.
128. Carbó N, Costelli P, Baccino FM, López-Soriano FJ, et al. Resveratrol, a natural product present in wine, decreases tumor growth in a rat tumor model. Biochem Biophys Res Commun 1999; 254: 739-43.
129. Asensi M, Medina I, Ortega A, Carretero J, et al. Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radic Biol Med 2002; 33: 387-98.
130. Ganapathy S, Chen Q, Singh KP, Shankar S, et al. Resveratrol enhances antitumor activity of TRAIL in prostate cancer xenografts through activation of FOXO transcription factor. PLoS One 2010; 5: e15627.
131. Seeni A, Takahashi S, Takeshita K, Tang M, et al. Suppression of prostate cancer growth by resveratrol in the transgenic rat for adenocarcinoma of prostate (TRAP) model. Asian Pac J Cancer Prev 2008; 9: 7-14.
132. Zhou HB, Chen JJ, Wang WX, Cai JT, et al. Anticancer activity of resveratrol on implanted human primary gastric carcinoma cells in nude mice. World J Gastroenterol 2005; 11: 280-4.
133. Yuan Y, Xue X, Guo RB, Sun XL, et al. Resveratrol enhances the antitumor effects of temozolomide in glioblastoma via ROSdependent AMPK-TSC-mTOR signaling pathway. CNS Neurosci Ther 2012; 18: 536-46.
134. Roy SK, Chen Q, Fu J, Shankar S, et al. Resveratrol inhibits growth of orthotopic pancreatic tumors through activation of FOXO transcription factors. PLoS One 2011; 6: e25166.
135. Kowalczyk MC, Kowalczyk P, Tolstykh O, Hanausek M, et al. Synergistic effects of combined phytochemicals and skin cancer prevention in SENCAR mice. Cancer Prev Res 2010; 3: 170-8.
136. Bishayee A, Dhir N. Resveratrol-mediated chemoprevention of diethylnitrosamine-initiated hepatocarcinogenesis: inhibition of cell proliferation and induction of apoptosis. Chem Biol Interact 2009; 179: 131-44.
137. Yang Hl, Chen Wq, Cao X, Du LF, et al. Caveolin-I enhances resveratrol-mediated cytotoxicity and transport in a hepatocellular carcinoma model. J Transl Med 2009; 7: 22.
138. Roy P, Kalra N, Prasad S, George J, et al. Chemopreventive Potential of resveratrol in Mouse Skin Tumors Through Regulation of Mitochondrial and PI3K/AKT Signaling Pathways. Pharm Res 2009; 26: 211-7.
139. Mbimba T, Awale P, Bhatia D, Geldenhuys WJ, et al. Alteration of hepatic proinflammatory cytokines is involved in the resveratrolmediated chemoprevention of chemically-induced hepatocarcinogenesis. Curr Pharm Biotechnol 2012; 13: 229-34.
140. Salado C, Olaso E, Gallot N, Valcarcel M, et al. Resveratrol prevents inflammation-dependent hepatic melanoma metastasis by inhibiting the secretion and effects of interleukin-18. J Transl Med 2011; 9: 59.
141. Wyke SM, Russell ST, Tisdale MJ. Induction of proteasome expression in skeletal muscle is attenuated by inhibitors of NFkappaB activation. Br J Cancer 2004; 91: 1742-50.
142. Lee HS, Ha AW, Kim WK. Effect of resveratrol on the metastasis of 4T1 mouse breast cancer cells in vitro and in vivo. Nutr Res Pract 2012; 6: 294-300.
143. Banerjee S, Bueso-Ramos C, Aggarwal BB. Suppression of 7, 12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: Role of nuclear factor-kappa B, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res 2002; 62: 4945-54.
144. Wu SL, Sun ZJ, Yu L, Meng KW, et al. Effect of resveratrol and in combination with 5-FU on murine liver cancer. World J Gastroenterol 2004; 10: 3048-52.
145. Fukui M, Yamabe N, Zhu BT. Resveratrol attenuates the anticancer efficacy of paclitaxel in human breast cancer cells in vitro and in vivo. Eur J Cancer 2010; 46: 1882-91.
146. El-Mowafy AM, El-Mesery ME, Salem HA, Al-Gayyar MM, et al. Prominent chemopreventive and chemoenhancing effects for resveratrol: unraveling molecular targets and the role of C-reactive protein. Chemotherapy 2010; 56: 60-5.
147. Tessitore L, Davit A, Sarotto I, Caderni G. Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting bax and p21(CIP) expression. Carcinogenesis 2000; 21: 1619-22.
148. Li ZG, Hong T, Shimada Y, Komoto I, et al. Suppression of Nnitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in F344 rats by resveratrol. Carcinogenesis 2002; 23: 1531-6.
149. Sengottuvelan M, Nalini N. Dietary supplementation of resveratrol suppresses colonic tumor incidence in 1, 2-dimethylhydrazinetreated rats by modulating biotransforming enzymes and aberrant crypt foci development. Br J Nutr 2006; 96: 145-53.
150. Huderson AC, Myers JN, Niaz MS, Washington MK, et al. Chemoprevention of benzo(a)pyrene-induced colon polyps in Apc (Min) mice by resveratrol. J Nutr Biochem 2012; 24: 713-24.
151. Oktem G, Uysal A, Oral O, Sezer ED, et al. Resveratrol attenuates doxorubicin-induced cellular damage by modulating nitric oxide and apoptosis. Exp Toxicol Pathol 2012; 64: 471-9.
152. Saleh MC, Connell BJ, Saleh TM. Resveratrol preconditioning induces cellular stress proteins and is mediated via NMDA and estrogen receptors. Neuroscience 2010; 166: 445-54.
153. Gurusamy N, Lekli I, Mukherjee S, Ray D, et al. Cardioprotection by resveratrol: a novel mechanism via autophagy involving the mTORC2 pathway. Cardiovasc Res 2010; 86: 103-12.
154. Huang JP, Huang SS, Deng JY, Chang CC, et al. Insulin and resveratrol act synergistically, preventing cardiac dysfunction in diabetes, but the advantage of resveratrol in diabetics with acute heart attack is antagonized by insulin. Free Radic Biol Med 2010; 49: 1710-21.
155. Lekli I, Szabo G, Juhasz B, Das S, et al. Protective mechanisms of resveratrol against ischemia/reperfusion-induced damage in hearts obtained from Zucker obese rats: the role of GLUT-4 and endothelin. Am J Physiol Heart Circ Physiol 2007; 294: H859-66.
156. Hung LM, Su MJ, Chen JK. Resveratrol protects myocardial ischemia-reperfusion injury through both NO-dependent and NOindependent mechanisms. Free Radic Biol Med 2004; 36: 774-81.
157. Dudley J, Das S, Mukherjee S, Das DK. Resveratrol, a unique phytoalexin present in red wine, delivers either survival signal or death signal to the ischemic myocardium depending on dose. J Nutr Biochem 2009; 20: 443-52.
158. Chen CJ, Yu W, Fu YC, Wang X, et al. Resveratrol protects cardiomyocytes from hypoxia-induced apoptosis through the SIRT1-FOXO1 pathway. Biochem Biophys Res Commun 2009; 378: 389-93.
159. Robich MP, Osipov RM, Nezafat R, Feng J, et al. Resveratrol improves myocardial perfusion in a swine model of hypercholesterolemia and chronic myocardial ischemia. Circulation 2010; 122: S142-9.
160. Azorín-Ortuño M, Yañéz-Gascón MJ, Pallarés FJ, Rivera J, et al. A dietary resveratrol-rich grape extract prevents the developing of atherosclerotic lesions in the aorta of pigs fed an atherogenic diet. J Agric Food Chem 2012; 60: 5609-20.
161. Delucchi F, Berni R, Frati C, Cavalli S, et al. Resveratrol treatment reduces cardiac progenitor cell dysfunction and prevents morphofunctional ventricular remodeling in type-1 diabetic rats. PLoS One 2012; 7: e39836.
162. Biala A, Tauriainen E, Siltanen A, Shi J, et al. Resveratrol induces mitochondrial biogenesis and ameliorates Ang II-induced cardiac remodeling in transgenic rats harboring human renin and angiotensinogen genes. Blood Press 2010; 19: 196-205.
163. Chan V, Fenning A, Iyer A, Hoey A, et al. Resveratrol improves cardiovascular function in DOCA-salt hypertensive rats. Curr Pharm Biotechnol 2011; 12: 429-36.
164. Aubin MC, Lajoie C, Clement R, Gosselin H, et al. Female rats fed a high-fat diet were associated with vascular dysfunction and cardiac fibrosis in the absence of overt obesity and hyperlipidemia: therapeutic potential of resveratrol. J Pharmacol Exp Ther 2008; 325: 961-8.
165. Rivera L, Moron R, Zarzuelo A, Galisteo M. Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem Pharmacol 2009; 77: 1053-63.
166. Miatello R, Vazquez M, Renna N, Cruzado M, et al. Chronic administration of resveratrol prevents biochemical cardiovascular changes in fructose-fed rats. Am J Hypertens 2005; 18: 864-70.
167. Bhatt SR, Lokhandwala MF, Banday AA. Resveratrol prevents endothelial nitric oxide synthase uncoupling and attenuates development of hypertension in spontaneously hypertensive rats. Eur J Pharmacol 2011; 667: 258-64.
168. Chen C, Yang W, Xueding C, Qi Z, et al. Resveratrol downregulates acute pulmonary thromboembolism-induced pulmonary artery hypertension via p38 mitogen-activated protein kinase and monocyte chemoattractant protein-1 signaling in rats. Life Sci 2012; 90: 721-7.
169. Akar F, Uludá O, Aydi{dotless}n A, Aytekin YA, et al. High-fructose corn syrup causes vascular dysfunction associated with metabolic disturbance in rats: protective effect of resveratrol. Food Chem Toxicol 2012; 50: 2135-41.
170. Behbahani J, Thandapilly SJ, Louis XL, Huang Y, et al. Resveratrol and small artery compliance and remodeling in the spontaneously hypertensive rat. Am J Hypertens 2010; 23: 1273-8.
171. Thandapilly SJ, Wojciechowski P, Behbahani J, Louis XL, et al. Resveratrol prevents the development of pathological cardiac hypertrophy and contractile dysfunction in the SHR without lowering blood pressure. Am J Hypertens 2010; 23: 192-6.
172. Louis XL, Thandapilly SJ, Mohankumar SK, Yu L, et al. Treatment with low-dose resveratrol reverses cardiac impairment in obese prone but not in obese resistant rats. J Nutr Biochem 2012; 23: 1163-9.
173. Rimbaud S, Ruiz M, Piquereau J, Mateo P, et al. Resveratrol improves survival, hemodynamics and energetics in a rat model of hypertension leading to heart failure. PLoS One 2011; 6: e26391.
174. Paffett ML, Hesterman J, Candelaria G, Lucas S, et al. Longitudinal in vivo SPECT/CT imaging reveals morphological changes and cardiopulmonary apoptosis in a rodent model of pulmonary arterial hypertension. PLoS One 2012; 7: e40910.
175. Lin JF, Lin SM, Chih CL, Nien MW, et al. Resveratrol reduces infarct size and improves ventricular function after myocardial ischemia in rats. Life Sci 2008; 83: 313-7.
176. Penumathsa SV, Thirunavukkarasu M, Koneru S, Juhasz B, et al. Statin and resveratrol in combination induces cardioprotection against myocardial infarction in hypercholesterolemic rat. J Mol Cell Cardiol 2007; 42: 508-16.
177. Al-Dissi AN, Weber LP. Resveratrol preserves cardiac function, but does not prevent endothelial dysfunction or pulmonary inflammation after environmental tobacco smoke exposure. Food Chem Toxicol 2011; 49: 1584-91.
178. Wojciechowski P, Juric D, Louis XL, Thandapilly SJ, et al. Resveratrol arrests and regresses the development of pressure overload-but not volume overload-induced cardiac hypertrophy in rats. J Nutr 2010; 140: 962-8.
179. Dolinsky VW, Chan AY, Robillard Frayne I, Light PE, et al. Resveratrol prevents the prohypertrophic effects of oxidative stress on LKB1. Circulation 2009; 119: 1643-52.
180. Planavila A, Iglesias R, Giralt M, Villarroya F. Sirt1 acts in association with PPAR to protect the heart from hypertrophy, metabolic dysregulation, and inflammation. Cardiovasc Res 2011; 90: 276-84.
181. Mizutani K, Ikeda K, Kawai Y, Yamori Y. Resveratrol attenuates ovariectomy-induced hypertension and bone loss in stroke-prone spontaneously hypertensive rats. J Nutr Sci Vitaminol 2000; 46: 78-83.
182. Ramar M, Manikandan B, Raman T, Priyadarsini A, et al. Protective effect of ferulic acid and resveratrol against alloxan-induced diabetes in mice. Eur J Pharmacol 2012; 690: 226-35.
183. Alturfan AA, Tozan-Beceren A, Sehirli AO, Demiralp E, et al. Resveratrol ameliorates oxidative DNA damage and protects against acrylamide-induced oxidative stress in rats. Mol Biol Rep 2012; 39: 4589-96.
184. Bagul PK, Middela H, Matapally S, Padiya R, et al. Attenuation of insulin resistance, metabolic syndrome and hepatic oxidative stress by resveratrol in fructose-fed rats. Pharmacol Res 2012; 66: 260-8.
185. Franco JG, Lisboa PC, Lima NS, Amaral TA, et al. Resveratrol attenuates oxidative stress and prevents steatosis and hypertension in obese rats programmed by early weaning. J Nutr Biochem 2012; doi. org/10. 1016/j. jnutbio. 2012. 06. 019.
186. Petrat F, de Groot H. Protection against severe intestinal ischemia/reperfusion injury in rats by intravenous resveratrol. J Surg Res. 2011; 167: e145-55.
187. Chen YR, Yi FF, Li XY, Wang CY, et al. Resveratrol attenuates ventricular arrhythmias and improves the long-term survival in rats with myocardial infarction. Cardiovasc Drugs Ther 2008; 22: 479-85.
188. Do GM, Jung UJ, Park HJ, Kwon EY, et al. Resveratrol ameliorates diabetes-related metabolic changes via activation of AMPactivated protein kinase and its downstream targets in db/db mice. Mol Nutr Food Res 2012; 56: 1282-91.
189. Kim S, Jin Y, Choi Y, Park T. Resveratrol exerts anti-obesity effects via mechanisms involving down-regulation of adipogenic and inflammatory processes in mice. Biochem Pharmacol 2011; 81: 1343-51.
190. Do GM, Kwon EY, Kim HJ, Jeon SM, et al. Long-term effects of resveratrol supplementation on suppression of atherogenic lesion formation and cholesterol synthesis in apo E-deficient mice. Biochem Biophys Res Commun 2008; 374: 55-9.
191. Gómez-Zorita S, Fernández-Quintela A, Macarulla MT, Aguirre L, et al. Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress. Br J Nutr 2012; 107: 202-10.
192. Roghani M, Baluchnejadmojarad T. Mechanisms underlying vascular effect of chronic resveratrol in streptozotocin-diabetic rats. Phytother Res 2010; 24: S148-54.
193. Robich MP, Osipov RM, Chu LM, Han Y, et al. Resveratrol modifies risk factors for coronary artery disease in swine with metabolic syndrome and myocardial ischemia. Eur J Pharmacol 2011; 664: 45-53.
194. Jeon BT, Jeong EA, Shin HJ, Lee Y, et al. Resveratrol attenuates obesity-associated peripheral and central inflammation and improves memory deficit in mice fed a high-fat diet. Diabetes 2012; 61: 1444-54.
195. Bujanda L, Hijona E, Larzabal M, Beraza M, et al. Resveratrol inhibits nonalcoholic fatty liver disease in rats. BMC Gastroenterol 2008; 8: 40.
196. Shang J, Chen LL, Xiao FX, Sun H, et al. Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase. Acta Pharmacol Sin 2008; 29: 698-706.
197. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006; 127: 1109-22.
198. Dal-Pan A, Blanc S, Aujard F. Resveratrol suppresses body mass gain in a seasonal non-human primate model of obesity. BMC Physiol 2010; 10: 11.
199. Baur JA, Pearson KJ, Price NL, Jamieson HA, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006; 444: 337-42.
200. Ramadori G, Gautron L, Fujikawa T, Vianna CR, et al. Central administration of resveratrol improves diet-induced diabetes. Endocrinology 2009; 150: 5326-33.
201. Sharma S, Misra CS, Arumugam S, Roy S, et al. Antidiabetic activity of resveratrol, a known SIRT1 activator in a genetic model for type-2 diabetes. Phytother Res 2011; 25: 67-73.
202. Kang W, Hong HJ, Guan J, Kim DG, et al. Resveratrol improves insulin signaling in a tissue-specific manner under insulin-resistant conditions only: in vitro and in vivo experiments in rodents. Metabolism 2012; 61: 424-33.
203. Gonzalez-Rodriguez A, Mas Gutierrez JA, Sanz-Gonzalez S, Ros M, et al. Inhibition of PTP1B restores IRS1-mediated hepatic insulin signaling in IRS2-deficient mice. Diabetes 2010; 59: 588-99.
204. Deng JY, Hsieh PS, Huang JP, Lu LS, et al. Activation of estrogen receptor is crucial for resveratrol-stimulating muscular glucose uptake via both insulin-dependent and-independent pathways. Diabetes 2008; 57: 1814-23.
205. Andersen G, Burkon A, Sulzmaier FJ, Walker JM, et al. High dose of dietary resveratrol enhances insulin sensitivity in healthy rats but does not lead to metabolite concentrations effective for SIRT1 expression. Mol Nutr Food Res 2011; 55: 1197-206.
206. Um JH, Park SJ, Kang H, Yang S, et al. AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes 2010; 59: 554-63.
207. Marchal J, Blanc S, Epelbaum J, Aujard F, et al. Effects of chronic calorie restriction or dietary resveratrol supplementation on insulin sensitivity markers in a primate, Microcebus murinus. PLoS One 2012; 7: e34289.
208. Akar F, Pektas MB, Tufan C, Soylemez S, et al. Resveratrol shows vasoprotective effect reducing oxidative stress without affecting metabolic disturbances in insulin-dependent diabetes of rabbits. Cardiovasc Drugs Ther 2011; 25: 119-31.
209. Sanchez-Fidalgo S, Cardeno A, Villegas I, Talero E, et al. Dietary supplementation of resveratrol attenuates chronic colonic inflammation in mice. Eur J Pharmacol 2010; 633: 78-84.
210. Singh UP, Singh NP, Singh B, Hofseth LJ, et al. Resveratrol (trans-3, 5, 4'-trihydroxystilbene) induces silent mating type information regulation-1 and down-regulates nuclear transcription factorkappaB activation to abrogate dextran sulfate sodium-induced colitis. J Pharmacol Exp Ther 2010; 332: 829-39.
211. Yao J, Wang JY, Liu L, Li YX, et al. Anti-oxidant effects of resveratrol on mice with DSS-induced ulcerative colitis. Arch Med Res 2010; 41: 288-94.
212. Zhang H, Morgan B, Potter BJ, Ma L, et al. Resveratrol improves left ventricular diastolic relaxation in type 2 diabetes by inhibiting oxidative/nitrative stress. Am J Physiol Heart Circ Physiol 2010; 299: H985-94.
213. Sehirli O, Tozan A, Omurtag GZ, Cetinel S, et al. Protective effect of resveratrol against naphthalene-induced oxidative stress in mice. Ecotoxicol Environ Saf 2008; 71: 301-8.
214. Sharma S, Chopra K, Kulkarni SK. Effect of insulin and its combination with resveratrol or curcumin in attenuation of diabetic neuropathic pain: participation of nitric oxide and TNF-alpha. Phytother Res 2007; 21: 278-83.
215. Martin AR, Villegas I, Sanchez-Hidalgo M, de la Lastra CA. The effects of resveratrol, a phytoalexin derived from red wines, on chronic inflammation induced in an experimentally induced colitis model. Br J Pharmacol 2006; 147: 873-85.
216. Kumar P, Padi SS, Naidu PS, Kumar A. Effect of resveratrol on 3-nitropropionic acid-induced biochemical and behavioral changes: possible neuroprotective mechanisms. Behav Pharmacol 2006; 17: 485-92.
217. Hong SW, Jung KH, Zheng HM, Lee HS, et al. The protective effect of resveratrol on dimethylnitrosamine-induced liver fibrosis in rats. Arch Pharm Research 2010; 33: 601-9.
218. Palsamy P, Subramanian S. Ameliorative potential of resveratrol on proinflammatory cytokines, hyperglycemia mediated oxidative stress, and pancreatic beta-cell dysfunction in streptozotocinnicotinamide-induced diabetic rats. J Cell Physiol 2010; 224: 423-32.
219. Sener G, Topaloglu N, Ozer SA, Ercan F, et al. Resveratrol alleviates bleomycin-induced lung injury in rats. Pulm Pharmacol Ther 2007; 20: 642-9.
220. Ara C, Kirimlioglu H, Karabulut AB, Coban S, et al. Protective effect of resveratrol against oxidative stress in cholestasis. J Surg Res 2005; 127: 112-7.
221. Larrosa M, Yanez-Gascon MJ, Selma MV, Gonzalez-Sarrias A, et al. Effect of a low dose of dietary resveratrol on colon microbiota, inflammation and tissue damage in a DSS-induced colitis rat model. J Agric Food Chem 2009; 57: 2211-20.
222. Inanaga K, Ichiki T, Matsuura H, Miyazaki R, et al. Resveratrol attenuates angiotensin II-induced interleukin-6 expression and perivascular fibrosis. Hypertens Res 2009; 32: 466-71.
223. Norata GD, Marchesi P, Passamonti S, Pirillo A, et al. Antiinflammatory and anti-atherogenic effects of cathechin, caffeic acid and trans-resveratrol in apolipoprotein E deficient mice. Atherosclerosis 2007; 191: 265-71.
224. Singh NP, Hegde VL, Hofseth LJ, Nagarkatti M, et al. Resveratrol (trans-3, 5, 4'-trihydroxystilbene) ameliorates experimental allergic encephalomyelitis, primarily via induction of apoptosis in T cells involving activation of aryl hydrocarbon receptor and estrogen receptor. Mol Pharmacol 2007; 72: 1508-21.
225. Lee M, Kim S, Kwon OK, Oh SR, et al. Anti-inflammatory and anti-asthmatic effects of resveratrol, a polyphenolic stilbene, in a mouse model of allergic asthma. Int Immunopharmacol 2009; 9: 418-24.
226. Foti Cuzzola V, Ciurleo R, Giacoppo S, Marino S, et al. Role of resveratrol and its analogues in the treatment of neurodegenerative diseases: focus on recent discoveries. CNS Neurol Disord Drug Targets 2011; 10: 849-62.
227. Kumar A, Naidu PS, Seghal N, Padi SS. Neuroprotective effects of resveratrol against intracerebroventricular colchicine-induced cognitive impairment and oxidative stress in rats. Pharmacology 2007; 79: 17-26.
228. Mudò G, Mäkelä J, Di Liberto V, Tselykh TV, et al. Transgenic expression and activation of PGC-1 protect dopaminergic neurons in the MPTP mouse model of Parkinson's disease. Cell Mol Life Sci 2012; 7: 1153-65.
229. Srivastava G, Dixit A, Yadav S, Patel DK, et al. Resveratrol potentiates cytochrome P450 2 d22-mediated neuroprotection in maneband paraquat-induced parkinsonism in the mouse. Free Radic Biol Med 2012; 52: 1294-306.
230. Ren J, Fan C, Chen N, Huang J, et al. Resveratrol pretreatment attenuates cerebral ischemic injury by upregulating expression of transcription factor Nrf2 and HO-1 in rats. Neurochem Res 2011; 36: 2352-62.
231. Della-Morte D, Dave KR, DeFazio RA, Bao YC, et al. Resveratrol pretreatment protects rat brain from cerebral ischemic damage via a sirtuin 1-uncoupling protein 2 pathway. Neuroscience 2009; 159: 993-1002.
232. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003; 425: 191-6.
233. Wood JG, Rogina B, Lavu S, Howitz K, et al. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 2004; 430: 686-9.
234. Valenzano DR, Terzibasi E, Genade T, Cattaneo A, et al. Resveratrol prolongs lifespan and retards the onset of age-related markers in a short-lived vertebrate. Curr Biol 2006; 16: 296-300.
235. Strong R, Miller RA, Astle CM, Baur JA, et al. Evaluation of Resveratrol, Green Tea Extract, Curcumin, Oxaloacetic Acid, and Medium-Chain Triglyceride Oil on Life Span of Genetically Heterogeneous Mice. J Gerontol A Biol Sci Med Sci. 2012; 68: 6-16.
236. Wang C, Wheeler CT, Alberico T, Sun X, et al. The effect of resveratrol on lifespan depends on both gender and dietary nutrient composition in Drosophila melanogaster. Age (Dordr) 2011; 35: 69-81.
237. Chandrashekara KT, Shakarad MN. Aloe vera or resveratrol supplementation in larval diet delays adult aging in the fruit fly, Drosophila melanogaster. J Gerontol A Biol Sci Med Sci 2011; 66: 965-71.
238. Somoza V. Resveratrol--current status and outlook. Mol Nutr Food Res 2011; 55: 1127-8.
239. Patel KR, Scott E, Brown VA, Gescher AJ, et al. Clinical trials of resveratrol. Ann N Y Acad Sci 2011; 1215: 161-9.
240. Smoliga JM, Baur JA, Hausenblas HA. Resveratrol and health--a comprehensive review of human clinical trials. Mol Nutr Food Res 2011; 55: 1129-41.
241. Chachay VS, Kirkpatrick CM, Hickman IJ, Ferguson M, et al. Resveratrol--pills to replace a healthy diet? Br J Clin Pharmacol 2011; 72: 27-38.
242. Timmers S, Auwerx J, Schrauwen P. The journey of resveratrol from yeast to human. Aging 2012; 4: 146-58.
243. Neves AR, Lucio M, Lima JL, Reis S. Resveratrol in medicinal chemistry: a critical review of its pharmacokinetics, drug-delivery, and membrane interactions. Curr Med Chem 2012; 19: 1663-81.
244. Smoliga JM, Vang O, Baur JA. Challenges of translating basic research into therapeutics: Resveratrol as an example. J Gerontol A Biol Sci Med Sci 2012; 67: 158-67.
245. Wang H, Yang YJ, Qian HY, Zhang Q, et al. Resveratrol in cardiovascular disease: what is known from current research? Heart Fail Rev 2012; 17: 437-48.
246. Walle T. Bioavailability of resveratrol. Ann N Y Acad Sci 2011; 1215: 9-15.
247. Azorín-Ortuño M, Yáñez-Gascón MJ, Vallejo F, Pallarés FJ, et al. Metabolites and tissue distribution of resveratrol in the pig. Mol Nutr Food Res 2011; 55: 1154-68.
248. Burkon A, Somoza V. Quantification of free and protein-bound trans-resveratrol metabolites and identification of trans-resveratrol-C/O-conjugated diglucuronides-two novel resveratrol metabolites in human plasma. Mol Nutr Food Res 2008; 52: 549-57.
249. Rotches-Ribalta M, Andres-Lacueva C, Estruch R, Escribano E, et al. Pharmacokinetics of resveratrol metabolic profile in healthy humans after moderate consumption of red wine and grape extract tablets. Pharmacol Res 2012; 66: 375-82.
250. Alfarás I, Pérez M, Juan ME, Merino G, et al. Involvement of breast cancer resistance protein (BCRP1/ABCG2) in the bioavailability and tissue distribution of trans-resveratrol in knockout mice. J Agric Food Chem 2010; 58: 4523-8.
251. Azorín-Ortuño M, Yáñez-Gascón MJ, González-Sarrías A, Larrosa M, et al. Effects of long-term consumption of low doses of resveratrol on diet-induced mild hypercholesterolemia in pigs: a transcriptomic approach to disease prevention. J Nutr Biochem 2012a; 23: 829-37.
252. Bode LM, Bunzel D, Huch M, Cho GS, et al. In vivo and in vitro metabolism of trans-resveratrol by human gut microbiota. Am J Clin Nutr 2013; 97: 295-309.
253. Nunes T, Almeida L, Rocha JF, Falcão A, et al. Pharmacokinetics of trans-resveratrol following repeated administration in healthy elderly and young subjects. J Clin Pharmacol 2009; 49: 1477-82.
254. Boocock DJ, Patel KR, Faust GE, Normolle DP, et al. Quantitation of trans-resveratrol and detection of its metabolites in human plasma and urine by high performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 848: 182-7.
255. Boocock DJ, Faust GE, Patel KR, Schinas AM, et al. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 2007; 16: 1246-52.
256. Azorín-Ortuño M, Yanéz-Gascón MJ, Pallarés FJ, Vallejo F, et al. Pharmacokinetic study of trans-resveratrol in adult pigs. J Agric Food Chem 2010; 58: 11165-71.
257. Vaz-da-Silva M, Loureiro AI, Falcao A, Nunes T, et al. Effect of food on the pharmacokinetic profile of trans-resveratrol. Int J Clin Pharmacol Ther 2008; 46: 564-70.
258. la Porte C, Voduc N, Zhang G, Seguin I, et al. Steady-State pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects. Clin Pharmacokinet 2010; 49: 449-54.
259. Vitaglione P, Sforza S, Galaverna G, Ghidini C, et al. Bioavailability of trans-resveratrol from red wine in humans. Mol Nutr Food Res 2005; 49: 495-504.
260. Patel KR, Brown VA, Jones DJ, Britton RG, et al. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res 2010; 70: 7392-9.
261. Hebden JM, Gilchrist PJ, Perkins AC, Wilson CG, et al. Stool water content and colonic drug absorption: contrasting effects of lactulose and codeine. Pharm Res 1999; 16: 1254-9.
262. Sheweita SA, Tilmisany AK. Cancer and phase II drugmetabolizing enzymes. Curr Drug Metab 2003; 4: 45-58.
263. Howells LM, Berry DP, Elliott PJ, Jacobson EW, et al. Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases--safety, pharmacokinetics, and pharmacodynamics. Cancer Prev Res (Phila) 2011; 4: 1419-25.
264. Nguyen AV, Martinez M, Stamos MJ, Moyer MP, et al. Results of a phase I pilot clinical trial examining the effect of plant-derived resveratrol and grape powder on Wnt pathway target gene expression in colonic mucosa and colon cancer. Cancer Manag Res 2009; 1: 25-37.
265. Sanders MA, Majumdar AP. Colon cancer stem cells: implications in carcinogenesis. Front Biosci 2011; 16: 1651-62.
266. Saif MW, Chu E. Biology of colorectal cancer. Cancer J 2010; 16: 196-201.
267. Brasnyó P, Molnár GA, Mohás M, Markó L, et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr 2011; 106: 383-9.
268. Avogaro A, de Kreutzenberg SV, Fadini GP. Oxidative stress and vascular disease in diabetes: is the dichotomization of insulin signaling still valid? Free Radic Biol Med 2002; 44: 1209-15.
269. Fujitaka K, Otani H, Jo F, Jo H, et al. Modified resveratrol Longevinex improves endothelial function in adults with metabolic syndrome receiving standard treatment. Nutr Res 2011; 31: 842-7.
270. Tomé-Carneiro J, Gonzálvez M, Larrosa M, García-Almagro FJ, et al. Consumption of a grape extract supplement containing resveratrol decreases oxidized LDL and ApoB in patients undergoing primary prevention of cardiovascular disease: a triple-blind, 6-month follow-up, placebo-controlled, randomized trial. Mol Nutr Food Res 2012; 56: 810-21.
271. Ehara S, Ueda M, Naruko T, Haze K, et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 2001; 103: 1955-60.
272. Contois JH, Warnick GR, Sniderman AD. Reliability of lowdensity lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B measurement. J Clin Lipidol 2011; 5: 264-72.
273. Tomé-Carneiro J, Gonzálvez M, Larrosa M, Yáñez-Gascón MJ, et al. One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease. Am J Cardiol 2012; 110: 356-63.
274. Bhatt JK, Thomas S, Nanjan MJ. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutr Res 2012; 32: 537-41.
275. Magyar K, Halmosi R, Palfi A, Feher G, et al. Cardioprotection by resveratrol: A human clinical trial in patients with stable coronary artery disease. Clin Hemorheol Microcirc 2012; 50: 179-87.
276. Crandall JP, Oram V, Trandafirescu G, Reid M, et al. Pilot Study of resveratrol in Older Adults With Impaired Glucose Tolerance. J Gerontol A Biol Sci Med Sci 2012; 67: 1307-12.
277. Maia H Jr, Haddad C, Pinheiro N, Casoy J. Advantages of the association of resveratrol with oral contraceptives for management of endometriosis-related pain. Int J Womens Health 2012; 4: 543-9.
278. Popat R, Plesner T, Davies F, Cook G, et al. A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma. Br J Haematol 2012; 160: 714-7.
279. Militaru C, Donoiu I, Craciun A, Scorei ID, et al. Oral resveratrol and calcium fructoborate supplementation in subjects with stable angina pectoris: Effects on lipid profiles, inflammation markers, and quality of life. Nutrition 2013; 29: 178-83.
280. Tomé-Carneiro J, Gonzálvez M, Larrosa M, Yáñez-Gascón MJ, et al. Grape resveratrol increases serum adiponectin and downregulates inflammatory genes in peripheral blood mononuclear cells: a triple-blind, placebo-controlled, one year clinical trial in patients with stable coronary artery disease. Cardiovasc Drugs Ther 2013; 27: 37-48.
281. Fulop T, Larbi A, Kotb R, de Angelis F, et al. Aging, immunity, and cancer. Discov Med 2011; 11: 537-50.
282. Wang JC, Bennett M. Aging and atherosclerosis: mechanisms, functional consequences, and potential therapeutics for cellular senescence. Circ Res 2012; 111: 245-59.
283. Ferrer I. Defining Alzheimer as a common age-related neurodegenerative process not inevitably leading to dementia. Prog Neurobiol 2012; 97: 38-51.
284. Ghanim H, Sia CL, Abuaysheh S, Korzeniewski K, et al. An antiinflammatory and reactive oxygen species suppressive effects of an extract of Polygonum cuspidatum containing resveratrol. J Clin Endocrinol Metab 2010; 95: E1-8.
285. Waters MJ. Seeking SOCS and sex steroids. Trends Endocrinol Metab 2003; 14: 149-51.
286. Sandhu MS, Dunger DB, Giovannucci EL. Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst 2002; 94: 972-80.
287. Scott E, Steward WP, Gescher AJ, Brown K. Resveratrol in human cancer chemoprevention-choosing the 'right' dose. Mol Nutr Food Res 2012; 56: 7-13.
288. Chow HH, Garland LL, Hsu CH, Vining DR, et al. Resveratrol modulates drug-and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prev Res (Phila) 2010; 3: 1168-75.
289. Kennedy DO, Wightman EL, Reay JL, Lietz G, et al. Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: a double-blind, placebo-controlled, crossover investigation. Am J Clin Nutr 2010; 91: 1590-7.
290. Ghanim H, Sia CL, Korzeniewski K, Lohano T, et al. A resveratrol and polyphenol preparation suppresses oxidative and inflammatory stress response to a high-fat, high-carbohydrate meal. J Clin Endocrinol Metab 2011; 96: 1409-14.
291. Bjørbaek C, El-Haschimi K, Frantz JD, Flier JS. The role of SOCS-3 in leptin signaling and leptin resistance. J Biol Chem 1999; 274: 30059-65.
292. Emanuelli B, Peraldi P, Filloux C, Chavey C, et al. SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor-alpha in the adipose tissue of obese mice. J BiolChem 2003; 276: 47944-49.
293. Wong RH, Howe PR, Buckley JD, Coates AM, et al. Acute resveratrol supplementation improves flow-mediated dilatation in overweight/obese individuals with mildly elevated blood pressure. Nutr Metab Cardiovasc Dis 2011; 21: 851-6.
294. Timmers S, Konings E, Bilet L, Houtkooper RH, et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab 2011; 14: 612-22.
295. De Groote D, Van Belleghem K, Devière J, Van Brussel W, et al. Effect of the intake of resveratrol, resveratrol phosphate, and catechin-rich grape seed extract on markers of oxidative stress and gene expression in adult obese subjects. Ann Nutr Metab 2012; 61: 15-24.
296. Heger A, Ferk F, Nersesyan A, Szekeres T, et al. Intake of a resveratrol-containing dietary supplement has no impact on DNA stability in healthy subjects. Mutat Res 2012; 749: 82-6.
297. Sisman AR, Kume T, Tas, G, Akan, P, et al. Comparison and evaluation of two C-reactive protein assays based on particleenhanced immunoturbidime-try. J Clin Lab Anal 2007; 21: 71-76.
298. Zhu W, Qin W, Zhang K, Rottinghaus GE, et al. Trans-resveratrol alters mammary promoter hypermethylation in women at increased risk for breast cancer. Nutr Cancer 2012; 64: 393-400.
299. Yoshino J, Conte C, Fontana L, Mittendorfer B, et al. Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. Cell Metab 2012; 16: 658-64.
300. Poulsen MM, Vestergaard PF, Clasen BF, Radko Y, et al. High-Dose Resveratrol Supplementation in Obese Men: An Investigator-Initiated, Randomized, Placebo-Controlled Clinical Trial of Substrate Metabolism, Insulin Sensitivity, and Body Composition. Diabetes 2012; 62: 1186-95.
301. Bo S, Ciccone G, Castiglione A, Gambino R, et al. Antiinflammatory and Antioxidant Effects of Resveratrol in Healthy Smokers. Curr Med Chem 2012; 20: 1323-31.
302. Fabbrocini G, Staibano S, De Rosa G, Battimiello V, et al. Resveratrol-containing gel for the treatment of acne vulgaris: a singleblind, vehicle-controlled, pilot study. Am J Clin Dermatol 2011; 12: 133-41.
303. Wu Y, Jia LL, Zheng YN, Xu XG, et al. Resveratrate protects human skin from damage due to repetitive ultraviolet irradiation. J Eur Acad Dermatol Venereol 2012; doi: 10. 1111/j. 1468-3083. 2011. 04414. x.
304. Buonocore D, Lazzeretti A, Tocabens P, Nobile V, et al. Resveratrol-procyanidin blend: nutraceutical and antiaging efficacy evaluated in a placebocontrolled, double-blind study. Clin Cosmet Investig Dermatol 2012; 5: 159-65.
305. Wu JM, Hsieh TC. Resveratrol: a cardioprotective substance. Ann N Y Acad Sci 2011; 1215: 16-21.
306. Agarwal B, Baur JA. Resveratrol and life extension. Ann N Y Acad Sci 2011; 1215: 138-43.
307. Burnett C, Valentini S, Cabreiro F, Goss M, et al. Absence of effects of Sir2 overexpression on lifespan in C. elegans and Drosophila. Nature 201; 477: 482-5.
308. Price NL, Gomes AP, Ling AJ, Duarte FV, et al. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab 2012; 15: 675-90.
309. Planas JM, Alfaras I, Colom H, Juan ME. The bioavailability and distribution of trans-resveratrol are constrained by ABC transporters. Arch Biochem Biophys 2012; 527: 67-73.
310. van de Wetering K, Burkon A, Feddema W, Bot A, et al. Intestinal breast cancer resistance protein (BCRP)/Bcrp1 and multidrug resistance protein 3 (MRP3)/Mrp3 are involved in the pharmacokinetics of resveratrol. Mol Pharmacol 2009; 75: 876-85.
311. Juan ME, González-Pons E, Planas JM. Multidrug resistance proteins restrain the intestinal absorption of trans-resveratrol in rats. J Nutr 2010; 140: 489-95.
312. Larrosa M, Tomé-Carneiro J, Yáñez-Gascón MJ, Alcántara D, et al. Preventive oral treatment with resveratrol pro-prodrugs drastically reduce colon inflammation in rodents. J Med Chem 2010; 53: 7365-76.
313. Hoshino J, Park EJ, Kondratyuk TP, Marler L, et al. Selective synthesis and biological evaluation of sulfate-conjugated resveratrol metabolites. J Med Chem 2010; 53: 5033-43.
314. Calamini B, Ratia K, Malkowski MG, Cuendet M, et al. Pleiotropic mechanisms facilitated by resveratrol and its metabolites. Biochem J 2010; 42: 273-82.
315. Andres-Lacueva C, Macarulla MT, Rotches-Ribalta M, Boto-Ordóñez M, et al. Distribution of resveratrol metabolites in liver, adipose tissue, and skeletal muscle in rats fed different doses of this polyphenol. J Agric Food Chem 2012; 60: 4833-40.
316. Calabrese EJ, Mattson MP, Calabrese V. Resveratrol commonly displays hormesis: occurrence and biomedical significance. Hum Exp Toxicol 2010; 29: 980-1015.
317. Willrich MA, Hirata MH, Hirata RD. Statin regulation of CYP3A4 and CYP3A5 expression. Pharmacogenomics 2009; 10: 1017-24.
318. Santos AC, Veiga F, Ribeiro AJ. New delivery systems to improve the bioavailability of resveratrol. Expert Opin Drug Deliv 2011; 8: 973-90.
319. Amri A, Chaumeil JC, Sfar S, Charrueau C. Administration of resveratrol: What formulation solutions to bioavailability limitations? J Control Release 2012; 158: 182-93.
320. Johnson JJ, Nihal M, Siddiqui IA, Scarlett CO, et al. Enhancing the bioavailability of resveratrol by combining it with piperine. Mol Nutr Food Res 2011; 55: 1169-76.
321. Harada N, Zhao J, Kurihara H, Nakagata N, et al. Resveratrol improves cognitive function in mice by increasing production of insulin-like growth factor-I in the hippocampus. J Nutr Biochem 2011; 22: 1150-9.
322. Espín JC, García-Conesa MT, Tomás-Barberán FA. Nutraceuticals: facts and fiction. Phytochemistry 2007; 68: 2986-3008.
323. Meng X, Maliakal P, Lu H, Lee MJ, et al. Urinary and plasma levels of resveratrol and quercetin in humans, mice, and rats after ingestion of pure compounds and grape juice. J Agric Food Chem 2004; 52: 935-42.
324. Urpí-Sardà M, Jáuregui O, Lamuela-Raventós RM, Jaeger W, et al. Uptake of diet resveratrol into the human low-density lipoprotein. Identification and quantification of resveratrol metabolites by liquid chromatography coupled with tandem mass spectrometry. Anal Chem 2005; 77: 3149-55.
325. Zamora-Ros R, Urpí-Sardà M, Lamuela-Raventós RM, Estruch R, et al. Diagnostic performance of urinary resveratrol metabolites as a biomarker of moderate wine consumption. Clin Chem 2006; 52: 1373-80.
326. Gresele P, Pignatelli P, Guglielmini G, Carnevale R, et al. Resveratrol, at concentrations attainable with moderate wine consumption, stimulates human platelet nitric oxide production. J Nutr 2008; 138: 1602-8.
327. Almeida L, Vaz-da-Silva M, Falcão A, Soares E, et al. Pharmacokinetic and safety profile of trans-resveratrol in a rising multipledose study in healthy volunteers. Mol Nutr Food Res 2009; 53: S7-15.
328. Ortuño J, Covas MI, Farre M, Pujadas M, et al. Matrix effects on the bioavailability of resveratrol in humans. Food Chem 2010; 4: 1123-30.